Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”774
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus657
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver dise572
Letter to the editor on “Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD”392
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future327
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)290
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement267
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023225
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity221
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign173
Preface162
Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges143
Navigating discordant non-invasive fibrosis assessments in metabolic dysfunction-associated steatotic liver disease: Implications for generalizability, clinical decision-making, and resource allocatio138
Reply to correspondence on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”122
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer103
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials96
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis89
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation88
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”81
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity79
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A78
HCC surveillance after curative treatment: A new frontier for abbreviated MRI: Editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after cura77
Clinical applications of immunogenomics in hepatocellular carcinoma73
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”72
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma71
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial69
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease69
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease69
2025 KASL clinical practice guidelines for management of hepatitis C68
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study68
Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”67
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c65
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment64
Toward hepatitis C virus elimination using artificial intelligence64
Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma61
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma60
Liver organoids: Current advances and future applications for hepatology60
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–202359
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma59
Rethinking lean metabolic dysfunction-associated steatotic liver disease: Unrecognized risk in lean populations: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: R58
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates 58
Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-asso57
Correspondence to editorial on “MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD”56
Ethanol‑specific stress and RAB25/GCN1 signaling: Emerging perspectives in alcohol‑associated liver disease: Editorial on “RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol56
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target55
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate55
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs54
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”53
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”52
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe52
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients wi50
2.3582689762115